|
gptkbp:instanceOf
|
gptkb:muscle_relaxant
gptkb:drug
|
|
gptkbp:approvedBy
|
1977 (US)
|
|
gptkbp:ATCCode
|
M03BX01
|
|
gptkbp:brand
|
gptkb:Gablofen
gptkb:Lioresal
|
|
gptkbp:CASNumber
|
1134-47-0
|
|
gptkbp:category
|
gptkb:centrally_acting_muscle_relaxants
GABA analogues
|
|
gptkbp:contraindication
|
hypersensitivity to baclofen
|
|
gptkbp:discoveredBy
|
gptkb:Ciba-Geigy
|
|
gptkbp:discoveredIn
|
1962
|
|
gptkbp:eliminationHalfLife
|
2–6 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasMolecularFormula
|
C10H12ClNO2
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-B receptor agonist
|
|
gptkbp:meltingPoint
|
206–208 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
coma
seizures
respiratory depression
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
2284
2198
CHEMBL715
DB00181
|
|
gptkbp:routeOfAdministration
|
oral
intrathecal
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
drowsiness
weakness
|
|
gptkbp:synonym
|
gptkb:beta-(Aminomethyl)-4-chlorobenzenepropanoic_acid
gptkb:chlorophenibut
|
|
gptkbp:UNII
|
H789N3FKE8
|
|
gptkbp:usedFor
|
multiple sclerosis
spasticity
spinal cord injury
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:4-aminobutanoic_acid
gptkb:GABA_B_receptor
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
baclofen
|